ClinicalTrials.gg
RecruitingNCT07087951Updated Aug 17, 2026

Efficacy of Gamma Auditory Stimulation for Cognitive Decline in Older Adults (Study 1)

An interventional study of Gamma auditory stimulation device (active setting) and Gamma auditory stimulation device (sham setting) in EEG Brain Oscillations, Alzheimer's Disease (AD) and Related Disorders and Cognitive Dysfunction, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Chang Gung Memorial Hospital.

Planned enrollment
11th of 25
70 · median 67
Started
2025
the only one that year
No phase
11 of 27
3 open now
Registered
25th of 27
by date

Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 25th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

Animal studies have shown that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, human studies using 40 Hz auditory stimulation alone remain limited. Therefore, this study will use a randomized, double-blind, placebo-controlled design to investigate the effects of 40 Hz auditory stimulation on cognitive function, EEG activity, sleep quality, and quality of life in older adults with mild cognitive impairment (MCI) or mild dementia.

Read the detailed description

Amyloid-beta (Aβ) aggregation and hyperphosphorylated tau protein tangles are widely recognized as the main pathological features of Alzheimer's disease (AD). Numerous domestic and international studies have demonstrated that 40 Hz gamma visual stimulation can effectively enhance 40 Hz gamma neural oscillations in healthy adults and older adults, improve cognitive performance and memory function in older adults and individuals with AD, and has shown good safety with no severe adverse effects.

Nevertheless, there are still several limitations to using 40 Hz visual stimulation as an intervention. Extended exposure to light sources may cause discomfort, affecting participants' willingness to continue. Prolonged light exposure may also increase the risk of seizures in photosensitive individuals. In addition, participants are required to actively fixate on the light source, which may reduce intervention adherence. Most importantly, the ecological validity of light-based stimulation remains low. Many studies require participants to gaze at light for at least five minutes or more, and daily sessions of up to an hour over several months are challenging to implement in daily life. To address these limitations, this project proposes using 40 Hz auditory stimulation as a more practical and sustainable intervention.

Moreover, animal studies have confirmed that 40 Hz auditory stimulation alone can improve spatial memory and reduce Aβ deposition. However, evidence on the independent application of 40 Hz auditory stimulation in humans remains limited. Therefore, this project will adopt a randomized, double-blind, placebo-controlled design to investigate the effects of 40 Hz auditory stimulation on cognitive function, EEG activity, sleep quality, and quality of life in older adults with mild cognitive impairment (MCI) or mild dementia.

03

Conditions studied

  • EEG Brain Oscillations
  • Alzheimer's Disease (AD) and Related Disorders
  • Cognitive Dysfunction

Keywords

  • endogenous gamma
  • EEG rhythms
  • resting-state EEG (rs-EEG)
  • Alzheimer's disease (AD)
  • Cognitive function
  • auditory stimulation
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age over 60 years old.
  2. ≤ 24
  3. CDR scores of 0.5 and 1
  4. Voluntary to sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of other psychiatric or neurological disorders
  2. Drug or alcohol addictions.
  3. Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.
  4. History of clinical stroke, major depressive disorder or dysthymic disorder according to the .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    40Hz music group

    The 40Hz music is combined with 40Hz sound and music.

    Device: Gamma auditory stimulation device (active setting)

  • Sham comparator
    Non-40Hz music group

    The non-40Hz music is combined with non-40Hz sound and music.

    Device: Gamma auditory stimulation device (sham setting)

Interventions

  • DeviceGamma auditory stimulation device (active setting)

    Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.

  • DeviceGamma auditory stimulation device (sham setting)

    Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) for 1 hour per day, 5 days a week, over 12 weeks, for a total of 60 hours.

06

What researchers measure

Primary outcomes

  1. Changes in neurophysiological function.

    The changes of power spectral density (PSD), response to gamma auditory stimulation and functional connectivity (FC) at each frequency band will be analyzed by EEG data from each subject.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

Secondary outcomes

  1. Change score of the Chinese version Verbal Learning Test (CVVLT).

    A nine-item of CVVLT (total recall, delayed recall) will be applied to measure the participant's memory ability, with a higher score indicating better performance.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  2. Change score of the WMS-III logical memory test

    WMS-III logical memory test (immediate recall, delayed recall) will be applied to measure the participant's memory ability. The maximum score is 25 for each recall trial, with a higher score indicating better performance

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  3. Change score of the Benson Complex Figure Test.

    Benson Complex Figure Test will be applied to measure the participant's memory ability. The maximum score is 17 for each trial, with a higher score indicating better performance.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  4. Change score of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)

    A neuropsychological test used to assess cognitive impairment, particularly in the context of Alzheimer's disease. The ADAS-Cog typically has a total score ranging from 0 to 70, with higher scores indicating greater cognitive impairment.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  5. Change score of the Cognitive Abilities Screening Instrument (CASI).

    CASI will be applied to measure the participant's general cognitive ability. The range of score is 0 to 100, with a higher score indicating better performance.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  6. Change score of the category Verbal Fluency Test (VFT).

    The category VFT will be applied to measure the participant's language and executive function, with a higher score indicates better performance.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  7. Performance changes of the Trail Making Test Form A/B (TMT-A/B)

    TMT-A/B will be applied to measure participant's attention and executive function. The number of seconds to complete each trial and the number of errors would be recorded, with a higher value indicating greater impairment.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  8. Performance changes of the Digit Span Test

    This is a widely used neuropsychological assessment that measures attention (Digit Span Forward), and working memory (Digit Span Backward). If the participant correctly repeats the digit sequence, the number of digits in the next sequence will increase. The test will be terminated after a set number of errors.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  9. Change score of the neuropsychiatric Inventory Questionnaire (NPI-Q)

    It evaluates 12 neuropsychiatric domains. For each symptom, the NPI-Q assesses its frequency (how often it occurs), severity (how intense it is), and the resulting caregiver distress associated with the symptom. Higher scores indicate more severe symptoms and greater caregiver burden.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  10. Change score of the Geriatric Depression Scale -short form (GDS-S)

    This tool consists of 15 yes-or-no questions and is commonly used to assess depression in older adults. A higher score indicates more severe depression.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  11. Change score of the Pittsburgh Sleep Quality Index (PSQI)

    It used to comprehensively assess participants' sleep quality over the past month with 19 questions. Each component is scored from 0 to 3, with higher scores indicating greater sleep problems. The total PSQI score, a sum of all component scores, will range from 0 to 21, where a score above 5 indicates poor sleep quality.

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  12. Change score of the 5-level EuroQol-5 Dimension (EQ-5D-5L)

    It used to assess an individual's quality of life with five questions and each dimension has five levels of severity. Additionally, the EQ-5D-5L includes a Visual Analog Scale, where respondents rate their overall health on a scale from 0 (the worst imaginable health) to 100 (the best imaginable health).

    Time frame: baseline (T1), through intervention completion, an average of 3 month (T2), three-month after intervention completion (T3)

  13. Safety/Adverse events outcome measure

    Adverse events, such as fatigue, headache, dizziness, dazzling, ear pain, and others, will be recorded using a 6-point Likert scale ranging from 'not at all' to 'extremely uncomfortable' (0 = not at all, 1 = minimal discomfort, 2 = mild discomfort, 3 = tolerable, 4 = severe discomfort, 5 = extreme discomfort). Participants will report adverse events (such as fatigue, headache, dizziness, dazzling, ocular pain, and others) using a 6-point Likert scale ranging from 'not at all' to 'extremely uncomfortable' after each light stimulation session.

    Time frame: Throughout the three-months intervention

  14. Device feasibility outcome measure

    Participants will answer a device feasibility questionnaire, include "how is the usability of the device", "How is your satisfaction of the user interface " ...etc. We will use a 6-point Likert scale ranging from 'not at all' to 'extremely good'.

    Time frame: Throughout the three-months intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 33 months is close to that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 28, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07087951
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Nov 14, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Chia-Hsiung Cheng, Ph.D.
Contact
ch.cheng@mail.cgu.edu.tw
+886-3-211800 ext. 3854

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion